Omission of USP Biological Reactivity Tests, In Vivo 〈88〉—Replacing 〈88〉 with an Expanded
Biological Reactivity Tests, In Vitro 〈87〉 and a Risk-Based Evaluation Framework
Desmond G. Hunt, Douglas E. Kiehl, Michael Eakins, Renaud Janssen
Correspondence should be addressed to: Desmond G. Hunt, Senior Principal Scientist, US Pharmacopeia, 12601 Twinbrook Parkway, Rockville, MD 20852-1790; email: dgh@usp.org.